![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Regeneron Begins Phase 3 Trial of Antibody Cocktail for COVID-19
Regeneron Begins Phase 3 Trial of Antibody Cocktail for COVID-19
![Regeneron logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Regeneron_Logo.png?t=1631745771&width=430)
Regeneron Pharmaceuticals has begun a phase 3 clinical trial in the U.S. of its antibody cocktail REGN-COV2 for the prevention of COVID-19 infections.
The trial is being conducted with the National Institutes for Allergy and Infectious Diseases and plans to enroll 2,000 patients across 100 sites.
The company has also launched two phase 2/3 trials evaluating the cocktail’s ability to treat patients already infected with COVID-19.
Upcoming Events
-
21Oct